RESUMO
OBJECTIVE: The study aimed at analyzing the serum expression of Immature Granulocyte percentage (IG %) and D-Dimer (D-D) in patients with severe pancreatitis and exploring their clinical diagnostic value. METHODS: Eighty-four cases with severe pancreatitis received in Shengjing Hospital, China Medical University from July 2020 to July 2023 were regarded as the study group and conducted for retrospective analysis. They were divided into a survival group (n = 62) and a death group (n = 22) based on the prognosis. Another 80 patients diagnosed with mild and moderate pancreatitis were selected as the control group. Serum IG % and D-D levels of all subjects were analyzed and the value of IG % and D-D in the evaluation of severe pancreatitis and its prognosis was conducted by Receiver Operating Characteristic (ROC) curve. RESULTS: The IG % and D-D levels in the study group were markedly higher than the control group (p < 0.05). The IG % and D-D level in the death group were observably higher than the survival group (p < 0.05). The Area Under the Curve (AUC) of IG % and D-D combined assessment for severe pancreatitis was 0.963, and the sensitivity and specificity were 98.75 %, 82.14 %, respectively. The AUC of IG % and D-D combined assessment for prognosis of severe pancreatitis was 0.814 with a sensitivity of 79.03 % and a specificity of 77.27 %. The efficiency of joint evaluation of the two indicators is superior to the individual evaluation. CONCLUSION: Serum IG % and D-D are highly expressed in patients with severe pancreatitis, which has important clinical value for the evaluation of severe pancreatitis and its prognosis.
Assuntos
Produtos de Degradação da Fibrina e do Fibrinogênio , Granulócitos , Pancreatite , Curva ROC , Índice de Gravidade de Doença , Humanos , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Feminino , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Pancreatite/sangue , Pancreatite/mortalidade , Pancreatite/diagnóstico , Adulto , Sensibilidade e Especificidade , Idoso , Biomarcadores/sangue , Contagem de Leucócitos , Estudos de Casos e ControlesRESUMO
BACKGROUND: Prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are eicosanoids involved in modulation of the antiviral immune response. Recent studies have identified increased levels of several eicosanoids in the plasma and bronchoalveolar lavage of patients with coronavirus disease (COVID-19). This study investigated correlations between plasma levels of PGE2 and LTB4 and clinical severity of COVID-19. METHODS: This cross-sectional study involved non-infected (n = 10) individuals and COVID-19 patients classified as cured (n = 13), oligosymptomatic (n = 29), severe (n = 15) or deceased (n = 11). Levels of D-dimer a, known COVID-19 severity marker, PGE2 and LTB4 were measured by ELISAs and data were analysed with respect to viral load. RESULTS: PGE2 plasma levels were decreased in COVID-19 patients compared to the non-infected group. Changes in PGE2 and LTB4 levels did not correlate with any particular clinical presentations of COVID-19. However, LTB4 was related to decreased SARS-CoV-2 burden in patients, suggesting that only LTB4 is associated with control of viral load. CONCLUSIONS: Our data indicate that PGE2/LTB4 plasma levels are not associated with COVID-19 clinical severity. Hospitalized patients with COVID-19 are treated with corticosteroids, which may influence the observed eicosanoid imbalance. Additional analyses are required to fully understand the participation of PGE2 receptors in the pathophysiology of COVID-19.
Assuntos
COVID-19 , Dinoprostona , Leucotrieno B4 , SARS-CoV-2 , Carga Viral , Humanos , COVID-19/sangue , COVID-19/virologia , COVID-19/imunologia , Leucotrieno B4/sangue , Estudos Transversais , Dinoprostona/sangue , Masculino , Feminino , Pessoa de Meia-Idade , SARS-CoV-2/fisiologia , Idoso , Adulto , Índice de Gravidade de Doença , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Produtos de Degradação da Fibrina e do Fibrinogênio/análiseRESUMO
Attenuated Total Reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy is an emerging technology in the medical field. Blood D-dimer was initially studied as a marker of the activation of coagulation and fibrinolysis. It is mainly used as a potential diagnosis screening test for pulmonary embolism or deep vein thrombosis but was recently associated with COVID-19 severity. This study aimed to evaluate the use of ATR-FTIR spectroscopy with machine learning to classify plasma D-dimer concentrations. The plasma ATR-FTIR spectra from 100 patients were studied through principal component analysis (PCA) and two supervised approaches: genetic algorithm with linear discriminant analysis (GA-LDA) and partial least squares with linear discriminant (PLS-DA). The spectra were truncated to the fingerprint region (1800-1000 cm-1). The GA-LDA method effectively classified patients according to D-dimer cutoff (≤0.5 µg/mL and >0.5 µg/mL) with 87.5 % specificity and 100 % sensitivity on the training set, and 85.7 % specificity, and 95.6 % sensitivity on the test set. Thus, we demonstrate that ATR-FTIR spectroscopy might be an important additional tool for classifying patients according to D-dimer values. ATR-FTIR spectral analyses associated with clinical evidence can contribute to a faster and more accurate medical diagnosis, reduce patient morbidity, and save resources and demand for professionals.
Assuntos
Espectroscopia de Infravermelho com Transformada de Fourier , Humanos , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Análise de Fourier , Análise Discriminante , Análise de Componente Principal , Proteínas Mutadas de Ataxia TelangiectasiaRESUMO
Introducción: La pandemia de COVID-19 continúa desafiando a los sistemas de salud. La estratificación de los pacientes afectados a partir de biomarcadores, estrategia menos invasiva, aún es controversial. Objetivo: Comprobar la capacidad discriminante de la ferritina, proteína C reactiva y dímero D entre pacientes con COVID-19 moderados y severos. Métodos: Se aplicó un diseño transversal entre junio y noviembre de 2021. Las variables cualitativas y la edad fueron registradas por revisión de la historia clínica. La determinación de los biomarcadores mencionados fue realizada en el momento de inclusión en el estudio con el empleo de reactivos Roche en el analizador Hitachi cobas c 311. Se empleó el programa estadístico SSPS para el análisis de datos. Resultados: Existió predominio de hipertensos en ambos grupos. La vacunación y el sexo femenino prevalecieron entre los moderados, mientras los hombres y las enfermedades crónicas entre los graves. Se manifestaron mayores niveles de los tres biomarcadores analizados en el grupo grave (Mann-Whitney p 0,5; p < 0,05). Conclusiones: La presencia de comorbilidades crónicas y de individuos no vacunados predominó entre los pacientes graves. Se demostró una estrecha correlación entre los biomarcadores analizados en ambos grupos de pacientes. Los biomarcadores mostraron capacidad discriminante entre la enfermedad COVID-19 moderada y grave(AU)
Introduction: The COVID-19 pandemic continues to challenge healthcare systems. The stratification of affected patients from biomarkers, a less invasive strategy, is still controversial. Objective: To check the discriminating capacity of ferritin, C-reactive protein and D-dimer in patients with moderate and severe COVID-19. Methods: A cross-sectional design was applied from June to November 2021. The qualitative variables and age were recorded by review of the patient's clinical records. The determination of the aforementioned biomarkers was carried out at the time of inclusion in the study using the Roche reagents in the HITACHI Cobas C 311 analyzer. The SPSS statistical program was used for analyzing dates. Results: There was a predominance of hypertensive patients in both groups. Vaccination and female sex prevailed among the moderate ones, while men and chronic diseases among the severe ones. Higher levels of the three analyzed biomarkers were observed in the severe group (Mann-Whitney test p < 0.05). The association between these was significant in both groups (Spearman correlation, p < 0.05). 366 μg/L of ferritin; 36.25 mg/L of C- reactive protein and 1.02 μg/mL of D-dimer, acceptably distinguished between severe and moderate (area under the curve ˃ 0.5; p < 0.05). Conclusions: The presence of chronic comorbidities and unvaccinated individuals predominated among severe patients. A close correlation was shown between the biomarkers analyzed in both patient groups. Biomarkers showed discriminating capacity between moderate and severe COVID-19 disease(AU)
Assuntos
Humanos , Masculino , Feminino , Proteína C-Reativa , Produtos de Degradação da Fibrina e do Fibrinogênio , Ferritinas , COVID-19/epidemiologia , Estudos TransversaisRESUMO
ABSTRACT Acute respiratory distress syndrome is a significant complication in critical care patients. COVID-19 (C19)-associated severe respiratory failure is related to it, and d-dimer rise predicts a worse outcome. To investigate the association between d-dimer and the severity of this respiratory syndrome, we conducted a study in C19 intubated patients. A retrospective, single-center observational study was conducted with 64 C19 adult intubated patients. Strata of d-dimer results between patients was evaluated using survival analysis. Survival was higher in mild respiratory distress patients. D-dimer showed poor sensitivity and specificity in predicting respiratory failure severity. Risk assessment for death showed a higher prevalence of admission d-dimer results (HR 1.335; 95% CI 0.695-2.564). Our sample confidently represented the medical profile of C19 severe patients. Sepsis development in C19 is associated with the inflammatory storm in respiratory distress syndrome. As the receiver operating curves show, the increase in d-dimer results is consistent with inflammation rather than a prognostic biomarker. As expected, severe respiratory distress patients presented higher mortality. In summary, d-dimer results are not associated with the prognosis of C19 respiratory distress syndrome patients.
RESUMO
On March 11, 2020, the World Health Organization (WHO) declared a new coronavirus infection caused by the SARS-CoV-2 virus as a pandemic, making it the 11th pandemic of the 20th and 21st centuries. This study investigated the clinical and laboratory results (D-dimer, conventional coagulation, and HbA1c biomarker concentrations) of 150 patients (75 male and 75 female) with confirmed COVID-19 pneumonia and 50 controls (25 male and 25 female). For disease diagnosis, all COVID-19 patients were given a Real-Time Reverse Transcription Polymerase Chain Reaction Assay (RT-PCR). The findings revealed that D-dimer and HbA1c levels in COVID-19 patients were significantly higher (P 0.001) at the time of admission; In COVID-19 patients, there was also a strong correlation between D-dimer levels and HbA1c levels (P 0.001). In conclusion, COVID-19 patients are more likely to have a poor prognosis if their D-dimer and HbA1c levels remain uncontrolled over a lengthy period. To lower the likelihood of a bad prognosis in COVID-19, patients with higher levels of D-dimer and HbA1c should be continuously monitored.
Em 11 de março de 2020, a Organização Mundial da Saúde (OMS) declarou uma nova infecção por coronavírus causada pelo vírus SARS-CoV-2 como uma pandemia, tornando-a a 11ª pandemia dos séculos XX e XXI. Este estudo investigou os resultados clínicos e laboratoriais (D-dímero, coagulação convencional e concentrações de biomarcadores HbA1c) de 150 pacientes (75 homens e 75 mulheres) com pneumonia por COVID-19 confirmada e 50 controles (25 homens e 25 mulheres). Para o diagnóstico da doença, todos os pacientes com COVID-19 receberam um Ensaio de Reação em Cadeia da Polimerase com Transcrição Reversa em Tempo Real (RT-PCR). Os achados revelaram que os níveis de D-dímero e HbA1c em pacientes com COVID-19 foram significativamente maiores (P 0,001) no momento da admissão. Em pacientes com COVID-19, também houve uma forte correlação entre os níveis de D-dímero e os níveis de HbA1c (P 0,001). Em conclusão, os pacientes com COVID-19 têm maior probabilidade de ter um prognóstico ruim se seus níveis de D-dímero e HbA1c permanecerem descontrolados por um longo período. Para diminuir a probabilidade de um mau prognóstico na COVID-19, os pacientes com níveis mais altos de D-dímero e HbA1c devem ser monitorados continuamente.
Assuntos
Humanos , Produtos de Degradação da Fibrina e do Fibrinogênio , Biomarcadores , COVID-19 , IraqueRESUMO
ABSTRACT Objective: The study aimed at analyzing the serum expression of Immature Granulocyte percentage (IG %) and D-Dimer (D-D) in patients with severe pancreatitis and exploring their clinical diagnostic value. Methods: Eighty-four cases with severe pancreatitis received in Shengjing Hospital, China Medical University from July 2020 to July 2023 were regarded as the study group and conducted for retrospective analysis. They were divided into a survival group (n = 62) and a death group (n = 22) based on the prognosis. Another 80 patients diagnosed with mild and moderate pancreatitis were selected as the control group. Serum IG % and D-D levels of all subjects were analyzed and the value of IG % and D-D in the evaluation of severe pancreatitis and its prognosis was conducted by Receiver Operating Characteristic (ROC) curve. Results: The IG % and D-D levels in the study group were markedly higher than the control group (p < 0.05). The IG % and D-D level in the death group were observably higher than the survival group (p < 0.05). The Area Under the Curve (AUC) of IG % and D-D combined assessment for severe pancreatitis was 0.963, and the sensitivity and specificity were 98.75 %, 82.14 %, respectively. The AUC of IG % and D-D combined assessment for prognosis of severe pancreatitis was 0.814 with a sensitivity of 79.03 % and a specificity of 77.27 %. The efficiency of joint evaluation of the two indicators is superior to the individual evaluation. Conclusion: Serum IG % and D-D are highly expressed in patients with severe pancreatitis, which has important clinical value for the evaluation of severe pancreatitis and its prognosis.
RESUMO
Elevated D-dimer levels at hospital admission may also indicate a higher likelihood of progressing to a severe or critical state. This study aimed to assess reactive oxygen species (ROS), non-enzymatic antioxidant reduced glutathione (GSH), and D-dimer levels in COVID-19 patients upon admission, examining their association with mortality outcomes. Data was collected from the medical records of 170 patients hospitalized in a referral hospital unit between March 2020 and December 2021. Patients were divided into two groups: the ward bed group (n = 87), comprising 51% with moderate clinical conditions, and the intensive care unit (ICU) group (n = 83), comprising 49% with severe conditions. The mean age was 59.4 years, with a male predominance of 52.4%. The overall death rate was 43%, with 30.6% in the moderate group and 69.4% in the severe group. The average time from symptom onset to hospitalization was 6.42 days. Results showed that non-survivors had high D-dimer and ROS counts, longer ICU stays, and worse saturation levels at admission. In conclusion, elevated ROS and D-dimer levels may contribute to worse outcomes in critically ill patients, potentially serving as specific and sensitive predictors of poor outcomes upon admission.
Assuntos
COVID-19 , Humanos , Masculino , Pessoa de Meia-Idade , Feminino , Espécies Reativas de Oxigênio , SARS-CoV-2 , Glutationa , Estresse OxidativoRESUMO
Resumen Introducción: los cuadros clínicos más graves y los desenlaces fatales resultantes de la infección por SARS-CoV-2 han sido asociados con una hiperactivación del sistema inmune con inmunotrombosis, proceso caracterizado por una respuesta inflamatoria exacerbada y de hipercoagulabilidad. Diferentes comorbilidades y factores genéticos de cada individuo podrían estar involucrados en un peor pronóstico. El objetivo de este estudio fue analizar si distintos biomarcadores relacionados con inflamación y coagulación, así como ciertas variables clínicas, identificadas al momento de la admisiónhospitalaria, podrían ser factores de riesgo asociados con una evolución clínica desfavorable. Asimismo, investigar la posible asociación entre la portación de las variantes genéticas factor V Leiden, la variante G20210A del gen del factor II y las variantes alélicas 10034C/T del gen del fibrinógeno gamma y 7872C/T del gen del factor XI con el desenlace clínico de pacientes COVID-19. Materiales y métodos: se incluyeron 204 pacientes adultos con diagnóstico confirmado de COVID-19+, hospitalizados durante la primera ola de la pandemia. Se registraron variables demográficas y clínicas incluyendo comorbilidades y se midieron diversos parámetros bioquímicos plasmáticos. Los pacientes se dividieron en dos grupos (sobrevida: n=141 y muerte: n=63) para comparar su evolución clínica. Resultados: se observó que los pacientes fallecidos eran de mayor edad y presentaban un índice de masa corporal más alto. Además, tenían recuentos de plaquetas y linfocitos más bajos, recuentos totales de leucocitos y neutrófilos más altos, una mayor relación neutrófilos/linfocitos y niveles más elevados de dímero D, ferritina y LDH en comparación con los supervivientes (p<0.05). Estableciendo puntos de corte, se encontró que un recuento de plaquetas <200.103/ul [OR=2.81, IC 95% (1.51-5.23)], un recuento de leucocitos >10.103/ul [OR=2.54, IC 95% (1.32-5.23)], un porcentaje de linfocitos <10% [OR=3.48, IC 95% (1.85-6.54]), un porcentaje de neutrófilos >70% [OR=2.82, IC 95% (1.43-5.59)], una relación neutrófilos/linfocitos >4 [OR=2.77, IC 95% (1.40-5.40)], niveles de dímero D >1500 ng/ml FEU [OR=2.67 IC 95% (1.33-5.37)] y ferritina >1000 ng/ml [OR=2.33, IC 95%(1.214.49)] al momento de la admisión hospitalaria estarían asociados con mayores posibilidades de sufrir un desenlace fatal. No se encontraron diferencias significativas en las distribuciones genotípicas de las variantes genéticas estudiadas entre ambos grupos. Discusión: acorde a investigaciones previas, se encontró que la edad, la obesidad y los niveles de marcadores hematológicos/plasmáticos medidos al momento de la admisión hospitalaria serían predictores de mal pronóstico en pacientes no inmunizados. Pese a la típica exacerbación de los mecanismos de coagulación en casos de COVID-19 severo, la portación de las variantes genéticas protrombóticas estudiadas no estaría asociada a un peor pronóstico.
Abstract Introduction: the most severe clinical presentations and the fatal outcomes resulting from SARS-CoV-2 infection have been associated with hyperactivation of the immune system with immunothrombosis, a process characterized by an exacerbated inflammatory response and hypercoagulability. Different comorbidities and genetic factors of each individual could be involved in a worse prognosis. The objective of this study was to analyze whether different biomarkers related to inflammation and coagulation, as well as certain clinical variables, addressed at the time of hospital admission, could be risk factors associated with an adverse clinical outcome. Likewise, to investigate the possible association between the carriage of the genetic variants factor V Leiden, G20210A variant in the factor II gene and the allelic variants 10034C/T in the fibrinogen gamma gene and 7872C/T in the factor XI gene and the clinical outcome of COVID-19 patients. Materials and methods: 204 adult patients with a confirmed diagnosis of COVID-19+, hospitalized during the first wave of the pandemic, were included. Demographic and clinical variables including comorbidities were recorded and various plasma biochemical parameters were measured. The patients were divided into two groups (survival: n=141 and death: n=63) to compare their clinical evolution. Results: it was found that the deceased patients were older and had a higher body mass index. They also had lower platelet and lymphocyte counts, higher total leukocyte and neutrophil counts, higher neutrophil/lymphocyte ratio, and higher levels of D-dimer, ferritin, and LDH compared to survivors (p<0.05). Establishing cut-off points, it was found that a platelet count <200.103/ul [OR=2.81, IC 95% (1.515.23)], a leukocyte count >10.103/ul [OR=2.54, IC 95% (1.32-5.23)], a percentage of lymphocytes <10% [OR=3.48, IC 95% (1.85-6.54]), a percentage of neutrophils >70% [OR=2.82, IC 95% (1.43-5.59)] a relationship neutrophils/lymphocytes >4 [OR=2.77, IC 95% (1.40-5.40)], D-dimer levels >1500 ng/ml FEU [OR=2.67 IC 95% (1.33-5.37)] and ferritin >1000 ng/ml [OR=2.33, IC 95%(1.21-4.49)] at the time of hospital admission would be associated with greater chances of suffering a fatal outcome. No significant differences were found in the genotypic distributions of the genetic variants studied between both groups. Discussion: according to previous investigations, it was found that age, obesity and the levels of hematological/plasma markers measured at the time of hospital admission, would be predictors of poor prognosis in non-immunized patients. Despite the typical exacerbation of coagulation mechanisms in cases of severe COVID-19, the carriage of the prothrombotic genetic variants studied would not be associated with a worse prognosis.
RESUMO
BACKGROUND: The COVID-19 pandemic has had a great impact on pregnant women due to the broad clinical spectrum of the disease. The present study investigated the profile of three biomarkers during hospital admission of pregnant women-D-dimer, C-reactive protein (CRP), and ferritin-and their correlation with the severity and outcome of COVID-19. METHODS: The cross-sectional study included 226 pregnant women hospitalized in the city of Belém, Pará, Northern Brazil, from April 2020 to July 2021. Epidemiological and laboratory data were obtained from medical records, and all pregnant women underwent RT-PCR molecular testing for the detection of SARS-CoV-2. RESULTS: In total, 121 (53.5%) were positive and 105 (46.5%) were negative for SARS-CoV-2 using RT-PCR. Most pregnant women (49.5%) with COVID-19 were between 26 and 34 years old, were residing in the interior of the state of Pará (51.2%), and were in the third gestational trimester (71.9%). In addition, 71.1% of them were admitted to the ward and 28.9% were admitted to the intensive care unit (ICU), with 90.9% surviving COVID-19. The concentrations of D-dimer (p = 0.0122) and ferritin (p ≤ 0.0001) were significantly higher among pregnant women with COVID-19, especially among those hospitalized in the ICU. CONCLUSION: Ferritin and D-dimer seem to serve as important biomarkers for the prognosis of COVID-19 in pregnant women, which was not observed for CRP.
Assuntos
COVID-19 , Humanos , Feminino , Gravidez , Adulto , COVID-19/diagnóstico , COVID-19/epidemiologia , Gestantes , Proteína C-Reativa/análise , SARS-CoV-2 , Estudos Transversais , Ferritinas , Pandemias , Brasil/epidemiologia , Biomarcadores , Estudos RetrospectivosRESUMO
Background: Microvascular lung vessels obstructive thromboinflammatory syndrome has been proposed as a possible mechanism of respiratory failure in COVID-19 patients. However, it has only been observed in post-mortem studies and has never been documented in vivo, probably because of a lack of CT scan sensitivity in small pulmonary arteries. The aim of the present study was to assess the safety, tolerability, and diagnostic value of optical coherence tomography (OCT) for the assessment of patients with COVID-19 pneumonia for pulmonary microvascular thromboinflammatory syndrome. Methods: The COVID-OCT trial was a multicenter, open-label, prospective, interventional clinical study. Two cohorts of patients were included in the study and underwent pulmonary OCT evaluation. Cohort A consisted of patients with COVID-19 with a negative CT scan for pulmonary thrombosis and elevated thromboinflammatory markers (D-dimer > 10,000 ng/mL or 5,000 < D-dimer < 10,000 ng/mL and one of: C-reactive Protein > 100 mg/dL, IL-6 > 6 pg/mL, or ferritin > 900 ng/L). Cohort B consisted of patients with COVID-19 and a CT scan positive for pulmonary thrombosis. The primary endpoints of the study were: (i) to evaluate the overall safety of OCT investigation in patients with COVID-19 pneumonia, and (ii) to report on the potential value of OCT as a novel diagnostic tool for the diagnosis of microvascular pulmonary thrombosis in COVID-19 patients. Results: A total of 13 patients were enrolled. The mean number of OCT runs performed in each patient was 6.1 ± 2.0, both in ground glass and healthy lung areas, achieving a good evaluation of the distal pulmonary arteries. Overall, OCT runs identified microvascular thrombosis in 8 patients (61.5%): 5 cases of red thrombus, 1 case of white thrombus, and 2 cases of mixed thrombus. In Cohort A, the minimal lumen area was 3.5 ± 4.6 mm2, with stenosis of 60.9 ± 35.9% of the area, and the mean length of thrombus-containing lesions was 5.4 ± 3.0 mm. In Cohort B, the percentage area obstruction was 92.6 ± 2.6, and the mean thrombus-containing lesion length was 14.1 ± 13.9 mm. No peri-procedural complications occurred in any of the 13 patients. Conclusion: OCT appears to be a safe and accurate method of evaluating the distal pulmonary arteries in hospitalized COVID-19 patients. Here, it enabled the first in vivo documentation of distal pulmonary arterial thrombosis in patients with elevated thromboinflammatory markers, even when their CT angiogram was negative for pulmonary thrombosis. Clinical trial registration: ClinicalTrial.gov, identifier NCT04410549.
RESUMO
Background: The severity of coronavirus disease 2019 (COVID-19) is related to several factors, including age, sex, and comorbidities (obesity, type 2 diabetes, and hypertension). However, systemic inflammation plays a fundamental role in COVID-19 pathophysiology. Several studies have described this association employing specific biomarkers that are not routinely used in clinical practice. On the other hand, very few reports in the literature focused on the analysis of the routine laboratory biomarkers to predict the outcome of severe COVID-19 patients. Objective: We aimed to analyze the dynamic inflammatory response using routine laboratory biomarkers to predict in-hospital mortality in Mexican patients with severe COVID-19. Methods: This is a cohort study including patients with severe COVID-19. Demographic characteristics were retrieved from medical charts and biochemical parameters were measured at hospital admission and subsequently on days 3, 5, 7, 10, 14, and 21 during the hospital stay; measurements were stopped when patients were discharged from the hospital (alive or death). Results: A total of 250 patients were included in the study, 40.8% of patients died. The analyzed routine laboratory parameters, such as serum levels of neutrophil-to-lymphocyte ratio, C-reactive protein, and D-dimer remained elevated in hospitalized patients who did not survive, whereas eosinophil and platelets were maintained at lower levels. In the multivariate analysis, leukocytes, and neutrophils were the best biomarkers for predicting mortality risk and were independent of age, gender, or comorbidities. Conclusion: Our results support the use of routine laboratory biomarkers as predictors of mortality in Mexican hospitalized patients with severe COVID-19.
RESUMO
BACKGROUND: D-dimer levels are significantly higher in COVID-19 patients with Pulmonary Thromboembolism (PTE) as compared to those without PTE, but its clinical utility is still uncertain. PURPOSE: To determine the D-dimer performance for ruling out PTE in patients with COVID-19. We also assessed clinical and laboratory factors associated with the presence of PTE on CT Pulmonary Angiogram (CTPA). METHODS: Retrospective study involving all patients who presented at a tertiary care hospital from March 2020 to May 2021 with severe acute respiratory syndrome from COVID-19, who underwent CTPA and had D-dimer collected within 48 hours from CTPA. The D-dimer ability to classify patients with or without PTE according to CTPA was evaluated. RESULTS: A total of 697 patients [382 (54.8%) men; mean (SD) age, 59 (20.5) years] were included, of which 71.5% required intensive care admission, 32.4% had PTE, and 35.6% died during hospitalization. PTE was independently associated with mortality [42.5% vs. 32.3%; p = 0.038]. D-dimer levels were higher in patients with PTE [9.1 (3.9; 20) vs. 2.3 (1.2; 5.1); p < 0.001]. Using the D-dimer cutoff of 0.5 µg/mL or above, sensitivity was 98.2% and specificity 5.7%. The 0.3 µg/mL threshold was associated with 100% of sensitivity for the presence of PTE, with which 99.1% of patients had increased values. ROC curve AUC was 0.77, demonstrating moderate discriminative power of D-dimers to detect PTE. CONCLUSIONS: D-dimer levels are higher among COVID-19 hospitalized patients with PTE as compared to those without PTE and have moderate discriminative power to detect PTE, but its use to exclude PTE in this population may have limited clinical utility.
Assuntos
COVID-19 , Embolia Pulmonar , Masculino , Humanos , Pessoa de Meia-Idade , Feminino , COVID-19/complicações , COVID-19/diagnóstico , Estudos Retrospectivos , Embolia Pulmonar/diagnóstico , Produtos de Degradação da Fibrina e do FibrinogênioRESUMO
RESUMEN Introducción: El tromboembolismo pulmonar (TEP) es una patología frecuente, que genera repercusiones hemodinámicas importantes y alta tasa de mortalidad, con alta incidencia en la enfermedad por coronavirus 2019 (COVID-19). Objetivo: Caracterizar el comportamiento clínico, de diagnóstico y pronóstico de los pacientes con sospecha de TEP antes y durante la pandemia de SARS-CoV-2. Metodología: Estudio de cohorte prospectiva de pacientes adultos llevados a angiotomografía de tórax por sospecha de TEP durante dos periodos de tiempo: a) pre-COVID-19: junio de 2018 a diciembre de 2019, y b) COVID-19: junio a diciembre de 2020. Se condujeron análisis bivariados y se construyeron curvas ROC calculando las áreas bajo la curva para el diagnóstico de TEP del dímero D y las reglas de predicción clínica. Resultados: Se incluyeron 302 pacientes pre COVID-19 y 55 pacientes con COVID-19. El dímero D muestra un desempeño moderado para diagnóstico del TEP con AUC: 0,73 (IC 95% 0,62-0,84) en fase pre-COVID-19 vs. 0,75 (IC95% 0,58-0,92) en fase COVID-19. Las áreas bajo la curva de cada una de las reglas de predicción clínica tuvieron un desempeño moderado a bajo en la fase pre-COVID-19 (AUC: 0,623 a 0,697), frente a una no discriminatoria en la fase COVID-19 (0,355 a 0,450). Conclusiones: Los factores de riesgo tradicional fueron poco prevalentes en pacientes con COVID-19 y TEP. Aunque el dímero D fue más alto en aquellos con TEP, la diferencia no fue estadísticamente significativa. Las reglas de predicción clínicas para el diagnóstico de TEP mostraron un bajo poder discriminativo en pacientes con COVID-19.
ABSTRACT Background: Pulmonary embolism (PE) is a frequent disease generating important hemodynamic effects and high mortality rate, with great incidence in coronavirus disease (COVID-19). Objective: The aim of this study was to characterize the clinical, diagnostic, and prognostic behavior of patients with suspected PE before and during the SARS-CoV-2 pandemic. Methods: A prospective cohort study of adult patients with suspected PE undergoing computed tomography pulmonary angiography was carried out during two periods: a) the pre-COVID-19 phase: June 2018 to December 2019, and b) during the COVID-19 phase: June to December 2020. Bivariate analyses were conducted and ROC curves were built calculating the areas under the curve (AUC) for D-dimer PE diagnosis and clinical prediction rules. Results: Three-hundred and two pre-COVID-19 patients and 55 patients with COVID-19 were included in the study. D-dimer showed a moderate performance for the diagnosis of PE, with AUC 0.73 (95% CI 0.62-0.84) in pre-COVID-19 phase vs. 0.75 (95% CI 0.58-0.92) in COVID-19 phase. The AUC of each of the clinical prediction rules had moderate to low performance in the pre-COVID-19 phase (AUC 0.623 to 0.697), with a non-discriminatory AUC in the COVID-19 phase (0.355 to 0.450). Conclusions: Traditional risk factors were poorly prevalent in patients with COVID-19 and PE. Although D-dimer was higher in those with PE, the difference was not statistically significant. Clinical prediction rules for PE diagnosis showed low discriminative power in COVID-19 patients.
RESUMO
PURPOSE: To determine whether VDPhys/VT is associated with coagulation activation and outcomes. MATERIALS AND METHODS: We enrolled patients with COVID-19 pneumonia who were supported by invasive mechanical ventilation and were monitored using volumetric capnography. Measurements were performed during the first 24 h of mechanical ventilation. The primary endpoint was the likelihood of being discharge alive on day 28. RESULTS: Sixty patients were enrolled, of which 25 (42%) had high VDPhys/VT (>57%). Patients with high vs. low VDPhys/VT had higher APACHE II (10[8-13] vs. 8[6-9] points, p = 0.002), lower static compliance of the respiratory system (35[24-46] mL/cmH2O vs. 42[37-45] mL/cmH2O, p = 0.005), and higher D-dimer levels (1246[1050-1594] ng FEU/mL vs. 792[538-1159] ng FEU/mL, p = 0.001), without differences in P/F ratio (157[112-226] vs. 168[136-226], p = 0.719). Additionally, D-dimer levels correlated with VDPhys/VT (r = 0.530, p < 0.001), but not with the P/F ratio (r = -0.103, p = 0.433). Patients with high VDPhys/VT were less likely to be discharged alive on day 28 (32% vs. 71%, aHR = 3.393[1.161-9.915], p = 0.026). CONCLUSIONS: In critically ill COVID-19 patients, increased VDPhys/VT was associated with high D-dimer levels and a lower likelihood of being discharged alive. Dichotomic VDPhys/VT could help identify a high-risk subgroup of patients neglected by the P/F ratio.
Assuntos
COVID-19 , Síndrome do Desconforto Respiratório , COVID-19/terapia , Capnografia , Humanos , Respiração Artificial , Espaço Morto Respiratório/fisiologia , Síndrome do Desconforto Respiratório/terapia , Volume de Ventilação Pulmonar/fisiologiaRESUMO
Resumen Introducción: El SARS-CoV-2 se desconocía hasta el brote en Wuhan, China en diciembre de 2019, las características ultraestructurales de este virus con predisposición a receptores expresados en los neumocitos tipo II (CD209L y ECA2) resultan en daño alveolar difuso y un tercio de los pacientes con SARS-CoV-2 cumplen criterios de SIRA con hipoxemia severa. Tras el curso severo de la enfermedad y alta mortalidad se reportó en estudios la asociación del dímero D (DD) con casos graves y atribuyéndose al estado protrombótico de la enfermedad, contribuyendo directamente en ventilación mecánica prolongada y muerte. Objetivo principal: Determinar los diferentes niveles de dímero D ante la presencia de hipoxemia severa en pacientes con neumonía por SARS-CoV-2 ingresados en la terapia intensiva. Material y métodos: Estudio transversal comparativo retrospectivo unicéntrico, se revisaron expedientes de pacientes mayores de 18 años que ingresaron a la Unidad de Cuidados Intensivos con diagnóstico de neumonía por SARS-CoV-2; se tomaron en cuenta los valores de DD al ingreso, al séptimo día y la relación PaO2/FiO2 de gasometrías arteriales. Definimos hipoxemia severa PaO2/FiO2 menor de 150 mmHg y tras prueba U de Mann-Whitney se evaluaron niveles de DD, curva de ROC y AUC para punto de cohorte de DD y la asociación con terapia de aporte de oxígeno y su desenlace con OR e IC95%. Resultados: Se estudiaron expedientes de 82 pacientes, 81.7% presentó hipoxemia severa al ingreso, y 74.4% al séptimo día; se reportó una mediana de DD de 1,410 ng/mL con hipoxemia severa y al séptimo día 2,238 ng/mL (p = 0.001). Curva ROC encontró DD 1,500 ng/mL como punto de cohorte asociado a hipoxemia severa (AUC: 0.808, IC al 95% 0.706-0.910). En escalas pronósticas reportó mayor puntuación, APACHE II (24 pts, p = 0.036), SOFA (12 pts, p = 0.012), y SAPS II (67 pts, p ≤ 0.0001); así como en defunciones (81.6%, p ≤ 0.0001, OR 16.50 IC al 95% 5.472-49.80). Conclusión: Dímero D mayor y/o igual a 1,500 ng/mL se asocia con hipoxemia severa y con mayor mortalidad al séptimo día de estancia en UCI, indicándonos que el DD es un potencial marcador temprano y útil para guiar la terapéutica y evaluar el pronóstico del paciente.
Abstract Introduction: SARS-CoV-2 was unknown until the outbreak in Wuhan, China in December 2019, the ultra-structural characteristics of this virus with predisposition to receptors expressed in type II pneumocytes (CD209L and ECA2), results in diffuse alveolar damage and a third of the patients with SARS-CoV-2 meet criteria for SIRA with severe hypoxemia. After the severe course of the disease and high mortality, the association of DD with severe cases was reported in studies and attributed to the prothrombotic state of the disease, directly contributing to prolonged mechanical ventilation and death. Main objective: To determine the different levels of DD in the presence of severe hypoxemia in patients with SARS-CoV-2 pneumonia admitted to intensive care. Material and methods: Cross-sectional retrospective single-center study, records of patients older than 18 years who were admitted to the intensive care unit with a diagnosis of SARS-CoV-2 pneumonia were reviewed; DD values on admission, on the seventh day and the PaO2/FiO2 ratio of arterial blood gases were considered. We defined severe hypoxemia PaO2/FiO2 less than 150 mmHg and after the Mann-Whitney U test, DD levels, ROC curve and AUC were evaluated for the DD cohort point and the association with oxygen supply therapy and its outcome with OR and HF 95%. Results: Records of 82 patients were studied, 81.7% presented severe hypoxemia on admission, and 74.4% on the seventh day; A median DD of 1,410 ng/mL was reported with severe hypoxemia and 2,238 ng/mL on the seventh day (p = 0.001). ROC curve found DD 1,500 ng/mL as a cohort point associated with severe hypoxemia (AUC: 0.808, 95% CI 0.706-0.910). On prognostic scales I report a higher score, APACHE II (24 pts, p = 0.036), SOFA (12 pts, p = 0.012), and SAPS II (67 pts, p ≤ 0.0001); as well as in deaths (81.6%, p ≤ 0.0001, OR 16.50 95% CI 5.472-49.80). Conclusion: DD greater than and/or equal to 1,500 ng/mL is associated with severe hypoxemia and higher mortality on the seventh day of stay in the ICU, indicating that DD is a potential early and useful marker to guide the therapy and evaluate the prognosis of the patient.
Resumo Introdução: O SARS-CoV-2 era desconhecido até o surto em Wuhan, China, em dezembro de 2019, as características ultraestruturais desse vírus com predisposição a receptores expressos em pneumócitos tipo II (CD209L e ACE2), resultando em dano alveolar difuso e um terço dos pacientes com SARS-Cov-2 atendem aos critérios para SDRA com hipoxemia grave. Após o curso grave da doença e alta mortalidade, estudos relataram a associação do D-Di com casos graves e atribuindo-se ao estado pró-trombótico da doença, contribuindo diretamente para ventilação mecânica prolongada e óbito. Objetivo principal: Determinar os diferentes níveis de dímero-D na presença de hipoxemia grave em pacientes com pneumonia por SARS-CoV-2 internados em terapia intensiva. Material e métodos: Estudo transversal comparativo retrospectivo unicêntrico, foram revisados prontuários de pacientes maiores de 18 anos admitidos na unidade de terapia intensiva com diagnóstico de pneumonia por SARS-CoV-2; foram considerados os valores de D-Di na admissão, no sétimo dia e a relação PaO2/FiO2 da gasometria arterial. Definimos hipoxemia grave PaO2/FiO2 menor que 150 mmHg e após o teste U de Mann-Whitney, os níveis de D-Di, curva ROC e AUC foram avaliados para o ponto de coorte D-Di e a associação com oxigenoterapia e seu desfecho com OR e IC 95%. Resultados: Foram estudados prontuários de 82 pacientes, 81.7% com hipoxemia grave na admissão e 74.4% no sétimo dia; relatou-se um D-Di médio de 1,410 ng/mL com hipoxemia grave e 2,238 ng/mL no sétimo dia (p = 0.001). A curva ROC encontrou D-Di 1,500 ng/mL como um ponto de coorte associado à hipoxemia grave (AUC: 0.808, IC 95% 0.706-0.910). Em escalas de prognóstico, APACHE II (24 pontos, p = 0.036), SOFA (12 pts, p = 0.012) e SAPS II (67 pts, p ≤ 0.0001); bem como em óbitos (81.6%, p ≤ 0.0001, OR 16.50, IC 95% 5.472-49.80). Conclusão: O D-Di maior e/ou igual a 1,500 ng/ml está associada à hipoxemia grave e maior mortalidade no sétimo dia de internação na UTI, indicando que o D-Di é um potencial marcador precoce e útil para orientar a terapia e avaliar o prognóstico do paciente.
RESUMO
Background: Nitazoxanide exerts antiviral activity in vitro and in vivo and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain. Methods: A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical improvement, hospital discharge, oxygen requirements, death, and adverse events within 14 days. Results: Of the 498 patients, 405 (202 in the nitazoxanide group and 203 in the placebo group) were included in the analyses. Admission to the intensive care unit did not differ between the groups (hazard ratio [95% confidence interval], 0.68 [0.38-1.20], p = 0.179); death rates also did not differ. Nitazoxanide improved the clinical outcome (2.75 [2.21-3.43], p < 0.0001), time to hospital discharge (1.37 [1.11-1.71], p = 0.005), and reduced oxygen requirements (0.77 [0.64-0.94], p = 0.011). C-reactive protein, D-dimer, and ferritin levels were lower in the nitazoxanide group than the placebo group on day 7. No serious adverse events were observed. Conclusions: Nitazoxanide, compared with placebo, did not prevent admission to the intensive care unit for patients hospitalized with COVID-19 pneumonia. Clinical Trial Registration: Brazilian Registry of Clinical Trials (REBEC) RBR88bs9x; ClinicalTrials.gov, NCT04561219.
RESUMO
Resumen: Introducción: La neumonía por SARS-CoV-2 se asocia a secreción importante de citoquinas y aglomeramiento de células inmunológicas, que activan las células endoteliales condicionando coagulopatía, afectando al pulmón en una fase temprana, con un fenotipo clínico del síndrome de dificultad respiratoria aguda (SDRA), que posteriormente progresa a respuesta inflamatoria sistémica desregulada por marcadores inflamatorios que causan mayor lesión endotelial generando trombosis. Muchos pacientes presentan niveles elevados de dímero D (DD), así como de proteína-C-reactiva (PCR), interleucina-6 (IL-6) y ferritina, supeditando la formación de coágulos, con la interrupción de la circulación (arterial o venosa) a cualquier nivel del sistema circulatorio. Objetivos: Determinar si existe relación entre los niveles elevados de marcadores inflamatorios y eventos trombóticos en pacientes con neumonía por SARS-CoV-2 con ventilación mecánica invasiva (VMI). Material y métodos: Realizamos estudio de una cohorte, observacional, retrospectivo y longitudinal, en pacientes que ingresaron a la Unidad de Terapia Respiratoria del Centro Médico ABC, de abril a julio de 2020, con diagnóstico de neumonía por SARS-CoV-2 con VMI. Utilizamos el programa STATA para el análisis estadístico. Efectuamos un análisis lineal de medidas repetitivas por regresión logística para evaluar el comportamiento cronológico de las variables inflamatorias. Posteriormente, ajustamos los marcadores inflamatorios con variables demográficas, para la obtención de certeza diagnóstica y predicción de riesgo de eventos trombóticos. Resultados: Analizamos un total de 100 pacientes, predominando el sexo masculino en 78%. El 18% presentó trombosis. Inicialmente, los marcadores inflamatorios estadísticamente significativos fueron DD (p = 0.010) con niveles de 1375.5 ng/mL (967-2651) y ferritina (p = 0.030) con niveles 1391.5 ng/mL (622-1779). Con el ajuste de variables inflamatorias por edad, género, índice de masa corporal (IMC) y escalas de gravedad, las variables estadísticamente significativas fueron DD (p = 0.001) y ferritina (p = 0.004), obteniendo certeza diagnóstica de 80.57% para predecir el riesgo de eventos trombóticos. Conclusión: El control estricto de los parámetros de laboratorio y un alto índice de sospecha son vitales para formular un enfoque de tratamiento personalizado para los pacientes, y también pueden ayudar a clasificar a los pacientes con alto riesgo de presentar eventos trombóticos. Nuestro modelo enfatiza que hay que tener precaución con niveles elevados de DD y ferritina.
Abstract: Introduction: SARS-CoV-2 pneumonia is associated with an important secretion of cytokines and agglomeration of immune cells, which activate endothelial cells conditioning coagulopathy, affecting the lung at an early stage, with a clinical phenotype of Acute Respiratory Distress Syndrome (ARDS), which later progresses to a systemic inflammatory response deregulated by inflammatory markers that cause greater endothelial injury generating thrombosis. Many patients present high levels of D-dimer (DD), as well as C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin, subordinating the formation of clots, with the interruption of circulation (arterial or venous) at any level of the circulatory system. Objectives: To determine if there is a relationship between elevated levels of inflammatory markers and thrombotic events in patients with SARS-CoV-2 pneumonia with invasive mechanical ventilation (IMV). Material and methods: We conducted an observational, retrospective and longitudinal cohort study in patients admitted to the Respiratory Therapy Unit of the ABC Medical Center, from April to July 2020, with a diagnosis of SARS-CoV-2 pneumonia with IMV. We use the STATA program for statistical analysis. We performed a linear analysis of repetitive measures by logistic regression to evaluate the chronological behavior of the inflammatory variables. Subsequently, we adjusted the inflammatory markers with demographic variables, to obtain diagnostic certainty and prediction of risk of thrombotic events. Results: We analyzed a total of 100 patients, the male sex prevailing in 78%. 18% had thrombosis. Initially the statistically significant inflammatory markers were DD (p = 0.010) with levels of 1375.5 ng/mL (967-2651) and ferritin (p = 0.030) with levels 1391.5 ng/mL (622-1779). With the adjustment of inflammatory variables by age, gender, Body Mass Index (BMI) and severity scales, the statistically significant variables were DD (p = 0.001) and ferritin (p = 0.004), obtaining a diagnostic certainty of 80.57% to predict risk of thrombotic events. Conclusion: Tight control of laboratory parameters and a high index of suspicion are vital to formulating a personalized treatment approach for patients, and can also help classify patients at high risk for thrombotic events. Our model emphasizes that caution must be exercised with elevated levels of DD and ferritin.
Resumo: Introdução: A pneumonia por SARS-CoV-2 está associada à secreção significativa de citocinas e aglomeração de células imunes, que ativam as células endoteliais, causando coagulopatia, afetando o pulmão em estágio inicial, com um fenótipo clínico de Síndrome do Desconforto Respiratório Agudo (SDRA), que posteriormente progride para uma resposta inflamatória sistêmica desregulada por marcadores inflamatórios que causam maior lesão endotelial gerando trombose. Muitos pacientes apresentam níveis elevados de D-dímero (DD), bem como de proteína C-reativa (PCR), Interleucina-6 (IL-6) e ferritina, causando formação de coágulos, com interrupção da circulação (arterial ou venosa) em qualquer nível do sistema circulatório. Objetivos: Determinar se existe uma relação entre níveis elevados de marcadores inflamatórios e eventos trombóticos em pacientes com pneumonia por SARS-CoV-2 com ventilação mecânica invasiva (VMI). Material e métodos: Foi realizado um estudo de coorte observacional, retrospectivo e longitudinal em pacientes internados na Unidade de Terapia Respiratória do Centro Médico ABC, de abril a julho de 2020, com diagnóstico de pneumonia por SARS-CoV-2 com VMI. Usamos o programa STATA para análise estatística. Realizamos uma análise linear de medidas repetitivas por regressão logística para avaliar o comportamento cronológico das variáveis inflamatórias. Posteriormente, ajustamos os marcadores inflamatórios com variáveis demográficas, para obter certeza diagnóstica e predizer o risco de eventos trombóticos. Resultados: Analisamos um total de 100 pacientes, com predominância do sexo masculino em 78%. 18% apresentaram trombose. Inicialmente, os marcadores inflamatórios estatisticamente significativos foram DD (p = 0.010) com níveis de 1375.5 ng/mL (967-2651) e ferritina (p = 0.030) com níveis de 1391.5 ng/mL (622-1779). Com o ajuste das variáveis inflamatórias por idade, sexo, índice de massa corporal (IMC) e escalas de gravidade, as variáveis estatisticamente significativas foram DD (p = 0.001) e ferritina (p = 0.004), obtendo-se certeza diagnóstica de 80.57% para predizer o risco de eventos trombóticos. Conclusão: O controle estrito dos parâmetros laboratoriais e um alto índice de suspeita são vitais na formulação de uma abordagem de tratamento personalizado para os pacientes, e também podem ajudar a classificar os pacientes com alto risco de apresentar eventos trombóticos. Nosso modelo enfatiza que deve-se ter cautela com níveis elevados de DD e ferritina.
RESUMO
Aim: Pulmonary disease burden and biomarkers are possible predictors of outcomes in patients with COVID-19 and provide complementary information. In this study, the prognostic value of adding quantitative chest computed tomography (CT) to a multiple biomarker approach was evaluated among 148 hospitalized patients with confirmed COVID-19. Materials & methods: Patients admitted between March and July 2020 who were submitted to chest CT and biomarker measurement (troponin I, D-dimer and C-reactive protein) were retrospectively analyzed. Biomarker and tomographic data were compared and associated with death and intensive care unit admission. Results: The number of elevated biomarkers was significantly associated with greater opacification percentages, lower lung volumes and higher death and intensive care unit admission rates. Total lung volume <3.0 l provided further stratification for mortality when combined with biomarker evaluation. Conclusion: Adding automated CT data to a multiple biomarker approach may provide a simple strategy for enhancing risk stratification of patients with COVID-19.
Assuntos
Biomarcadores/análise , COVID-19/diagnóstico , Tórax/diagnóstico por imagem , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Proteína C-Reativa/análise , COVID-19/mortalidade , COVID-19/virologia , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Mortalidade Hospitalar , Humanos , Unidades de Terapia Intensiva , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Fatores de Risco , SARS-CoV-2/genética , SARS-CoV-2/isolamento & purificação , Tomografia Computadorizada por Raios X , Troponina I/sangueRESUMO
Background: The values of viral load in COVID-19 disease have gained relevance, seeking to understand its prognostic value and its behavior in the course of the disease, although there have been no conclusive results. In this study we sought to analyze serum viral load as a predictor of clinical outcome of the disease, as well as its association with inflammatory markers. Methods: An observational and retrospective study in a private hospital in North Mexico, patients with SARS-COV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) were followed through clinical outcome, viral load measurement, quantification of inflammatory markers and lymphocyte subpopulations. For the analysis, multiple regression models were performed. Results: We studied 105 patients [47 (SD 1.46) years old, 68.6% men]. After analysis with multiple regression models, there was an association between viral load at admission and vaccination schedule (ß-value=-0.279, p= 0.007), age (ß-value= 0.010, p = 0.050), mechanical ventilation (ß-value= 0.872, p = 0.007), lactate dehydrogenase (ß-value= 1.712, p= 0.004), D-dimer values at admission (ß-value= 0.847, p= 0.013) and subpopulation of B lymphocytes at admission (ß-value= -0.527, p= 0.042). There was no association with days of hospitalization, use of nasal prongs or high flux mask. Peak viral load (10 days after symptoms onset) was associated with peak IL-6 (ß-value= 0.470, p= 0.011). Peak viral load matched with peak procalcitonin and minimal lymphocyte values. C-reactive protein peak was before the peak of viral load. The minimum value viral load was documented on day 12 after symptom onset; it matched with the minimum values of IL-6 and ferritin, and the peak of D-dimer. Conclusions: SARS-COV-2 admission viral load is associated with vaccination status, mechanical ventilation, and different inflammatory markers.